Merrimack Pharmaceuticals Inc logo

MACK

Merrimack Pharmaceuticals Inc

$4.14

Earnings Summary

Revenue
$0Mn
Net Profits
$-0.13Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Merrimack Pharmaceuticals Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Merrimack Pharmaceuticals Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Merrimack Pharmaceuticals Inc’s net profit jumped 81.03% since last year same period to $-0.13Mn in the Q1 2022. On a quarterly growth basis, Merrimack Pharmaceuticals Inc has generated 71.86% jump in its net profits since last 3-months.

Net Profit Margins:

Merrimack Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Merrimack Pharmaceuticals Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Merrimack Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.64
EPS Estimate Current Year
-0.64

Highlights

EPS Estimate Current Quarter:

Merrimack Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.64 - a -137.04% fall from last quarter’s estimates.

EPS Estimate Current Year:

Merrimack Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.64.

Key Ratios

Key ratios of the Merrimack Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.01
Return on Assets (ROA)
-0.09
Return on Equity (ROE)
-0.11
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Merrimack Pharmaceuticals Inc’s earning per share (EPS) jumped 82.69% since last year same period to -0.01 in the Q1 2022. This indicates that the Merrimack Pharmaceuticals Inc has generated 82.69% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Merrimack Pharmaceuticals Inc’s return on assets (ROA) stands at -0.09.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Merrimack Pharmaceuticals Inc’s return on equity (ROE) stands at -0.11.

Dividend Per Share (DPS):

Merrimack Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2018-05-08
-1.15
-1.33
-15.65%
2018-08-07
-1.28
-1.33
-3.91%
2019-03-06
-0.64
-0.78
-22.47%
2018-11-07
-0.27
0.3
211.11%

Company Information

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. in April 2017. These milestone payments would be payable by Ipsen upon approval by the U.S. Food and Drug Administration ('FDA') of ONIVYDE® for certain additional clinical indications. ONIVYDE® is already approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. This existing approval is unrelated to any future potential milestone payments. Merrimack's agreement with Ipsen does not require Ipsen to provide Merrimack with any information on the progress of ONIVYDE® clinical trials that is not publicly available. Merrimack is also entitled to receive up to $54.5 million in contingent milestone payments related to its sale of anti-HER3 programs to Elevation Oncology (formerly 14ner Oncology, Inc.) in July 2019. The Company is seeking potential acquirers for its remaining preclinical assets.

Organisation
Merrimack Pharmaceuticals Inc
Industry
Health Technology